Sugi Predict

Sugi Predict / Compounds / SCHEMBL1159772

SCHEMBL1159772

SCHEMBL1159772

CC1CCN(C(=O)OC(C)(C)C)CC1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.48
▸ GPR119 Q8TDV5 3/20 0.46
▸ RECQL P46063 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.45
▸ MAPT P10636 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ USP30 Q70CQ3 2/20 0.43
▸ NR1H2 P55055 1/20 0.42
▸ JAK2 O60674 1/20 0.42
▸ JAK1 P23458 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ PTPN2 P17706 1/20 0.42
▸ PTPN1 P18031 1/20 0.42
▸ PTPN6 P29350 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25226719 1.00 HPGD (0.48) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL1935439 1.00 HPGD (0.48) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL1159770 1.00 HPGD (0.48) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL13390662 1.00 HPGD (0.48) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL16584336 1.00 HPGD (0.48) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL4533109 0.89 HPGD (0.49) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL4533115 0.89 HPGD (0.49) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL4533108 0.89 HPGD (0.49) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL408313 0.87 RECQL (0.49) HPGDGPR119RECQLEPHX1HSD17B10
SCHEMBL2158178 0.87 RECQL (0.49) HPGDGPR119RECQLEPHX1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 — — EP disclosed
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2025-11-18 — — US disclosed
EP-4616913-A2 GCN2 INHIBITORS AND USES THEREOF Merck Patent GmbH (DE) 2025-09-17 — — EP disclosed
EP-3746075-B1 GCN2 INHIBITORS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-09-03 — — EP disclosed
CN-118005640-A GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-05-10 — — CN disclosed
CN-111918651-B GCN2 inhibitors and uses thereof 默克专利股份有限公司 2024-01-30 — — CN disclosed
CN-112300172-B Bruton tyrosine kinase inhibitors 比奥根MA公司 2024-01-16 — — CN disclosed
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2023-09-14 — — US disclosed
EP-4192833-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES Richter Gedeon Nyrt. (HU) 2023-06-14 — — EP disclosed
CN-116075514-A Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives 吉瑞工厂 2023-05-05 — — CN disclosed
WO-2011012540-A1 TRICYCLIC INHIBITORS OF JAK F. HOFFMANN-LA ROCHE AG (CH) 2011-02-03 — — WO disclosed
US-20110021425-A1 TRICYCLIC INHIBITORS OF JAK BILLEDEAU ROLAND JOSEPH 2011-01-27 — — US disclosed
US-20100093706-A1 MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS PREXA PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20100093706-A1 MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS PREXA PHARMACEUTICALS, INC. (US) 2010-04-15 — — US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 — — US disclosed
WO-2009152133-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-12-17 — — WO disclosed
WO-2009152133-A1 NOVEL TRICYCLIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-12-17 — — WO disclosed
CN-101573334-A Multi-mediator transporter inhibitors for the treatment of central nervous system disorders PREXA PHARMACEUTICALS INC (US) 2009-11-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312338-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 HPGD 391/4885GPR119 1201/4885RECQL 3647/4885
US-20100093706-A1 MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SLC6A4, SLC18A2, SLC6A2 HPGD 3138/4885GPR119 164/4885RECQL 627/4885
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES GABRA5, GABRA1, P2RX5 HPGD 1106/4885GPR119 103/4885RECQL 1785/4885
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, GABRA1, P2RX5 HPGD 1106/4885GPR119 103/4885RECQL 1785/4885
US-20110021425-A1 TRICYCLIC INHIBITORS OF JAK JAK3, JAK1, JAK2 HPGD 4092/4885GPR119 2503/4885RECQL 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback